Yawning behavior for preclinical drug evaluation
Furukawa, T.
Methods and Findings in Experimental and Clinical Pharmacology 18(2): 141-155
1996
ISSN/ISBN: 0379-0355 PMID: 8740246 Document Number: 454910
Document emailed within 1 workday
Related Documents
Hashimoto, K. 2003: Preclinical evaluation of drug induced QT prolongation Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 121(6): 408-410Stelzig, S.; Hoffmann, W. 1988: The effect of reserpine pretreatment on yawning behavior in rats Die Pharmazie 43(9): 656
Ushijima, I.; Mizuki, Y.; Imaizumi, J.; Yamada, M.; Noda, Y.; Yamada, K.; Furukawa, T. 1985: Characteristics of yawning behavior induced by apomorphine, physostigmine and pilocarpine Archives Internationales de Pharmacodynamie et de Therapie 273(2): 196-201
Osieka, R. 1984: Human malignant melanoma: preclinical and clinical drug evaluation Behring Institute Mitteilungen 74: 353-367
Kelland, L.R.; Abel, G.; McKeage, M.J.; Jones, M.; Goddard, P.M.; Valenti, M.; Murrer, B.A.; Harrap, K.R. 1993: Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug Cancer Research 53(11): 2581-2586
Sun, D.; Yu, L.X.; Hussain, M.A.; Wall, D.A.; Smith, R.L.; Amidon, G.L. 2004: In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome Current Opinion in Drug Discovery and Development 7(1): 75-85
Venditti, J.M. 1981: Preclinical drug development: rationale and methods Seminars in Oncology 8(4): 349-361
Cushion, M.T.; Walzer, P.D. 2009: Preclinical drug discovery for new anti-pneumocystis compounds Current Medicinal Chemistry 16(20): 2514-2530
Zhang, Y.; Huang, G.; Yu, Y.; Han, J.; Yu, P. 2006: Preparation of ondansetron hydrochloride sustained-release tablet evaluation of its and drug release behavior in vitro Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 23(3): 597-600; 614
Gonschior, P.; Wilensky, R.; March, K.; Höfling, B. 1996: Local drug administration systems, preclinical and clinical use: perspectives and limitations Zeitschrift für Kardiologie 85(3): 155-165
Chabbert, Y.A. 1983: Moxalactam: preclinical evaluation La Semaine des Hopitaux: Organe Fonde Par l'Association d'Enseignement Medical des Hopitaux de Paris 59(26): 1943-1946
Bohdanecká, M.; Schück, O.; Reitschlägerová, V.; Sedivý, J. 1990: Preclinical modeling of the possible effect of acute uremia on drug resorption in the gastrointestinal tract Casopis Lekaru Ceskych 129(45): 1431-1433
Lavelle, F.; Bissery, M.C.; André, S.; Roquet, F.; Riou, J.F. 1996: Preclinical evaluation of CPT-11 and its active metabolite SN-38 Seminars in Oncology 23(1 Suppl 3: 11-20
Bazan, M.T.; Seale, N.S. 1982: A technique for immediate evaluation of preclinical exercises Journal of Dental Education 46(12): 726-728
Danhof, M.; Visser, S.A. G. 2002: Pharmaco-electroencephalography and pharmacokinetic-pharmacodynamic modeling in drug development: focus on preclinical steps Methods and Findings in Experimental and Clinical Pharmacology 24 Suppl D: 127-128
Kelner, M.J.; McMorris, T.C.; Beck, W.T.; Zamora, J.M.; Taetle, R. 1987: Preclinical evaluation of illudins as anticancer agents Cancer Research 47(12): 3186-3189
Taetle, R.; Howell, S.B. 1983: Preclinical re-evaluation of benzaldehyde as a chemotherapeutic agent Cancer Treatment Reports 67(6): 561-566
Bardzinski, M.A.; Light, E.I.; Rakow, B.; Kuchmas, J. 1985: Evaluation of a Ag-In-Pd casting alloy for preclinical teaching Journal of Dental Education 49(8): 589-591
Wong, A.Y.; Watson, J.F.; Thye, R.P. 1979: Evaluation of predictor variables for a self-instructional preclinical course Journal of Dental Education 43(12): 637-640
Churin, A.A.; Karpova, G.V.; Fomina, T.I.; Vetoshkina, T.V.; Dubskaia, T.I.; Voronova, O.L.; Filimonov, V.D.; Belianin, M.L.; Usov, V.I. 2008: Preclinical toxicological evaluation of Pentamang and Mangascan Eksperimental'naia i Klinicheskaia Farmakologiia 71(4): 49-52